Peptide LibraryResearch statistics
Retatrutide research: publications and trials
At a glance
Publications, all years
138
Since 2022
Publications in 2026 so far
56
Through November 1, 2026
Human clinical research
14.1%
19 of 135 classified
Registered clinical trials
34
ClinicalTrials.gov
Randomized controlled trials
12
Publications reporting an RCT in people
Systematic reviews and meta-analyses
23
Preclinical studies
14.1%
15 animal · 4 in vitro · 0 computational
Records that only mention it
61
Not counted above
Status in the library: In clinical trials. Groups: GLP-1 receptor agonists. 3 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Retatrutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2022 | 1 | 1 | 0 | 0 | 2 |
| 2023 | 2 | 1 | 4 | 6 | 13 |
| 2024 | 1 | 1 | 21 | 4 | 27 |
| 2025 | 5 | 6 | 27 | 2 | 40 |
| 2026 (to date) | 10 | 10 | 26 | 10 | 56 |
Study types
| Review | 55 |
|---|---|
| Editorial, letter or other | 19 |
| Animal study | 15 |
| Systematic review | 13 |
| Randomized controlled trial | 12 |
| Meta-analysis | 10 |
| In vitro study | 4 |
| Case report | 3 |
| Not yet classified | 3 |
| Other clinical trial | 2 |
| Observational human study | 2 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 90 |
|---|---|
| Obesity and weight management | 87 |
| Endocrinology | 50 |
| Gastrointestinal | 20 |
| Cardiovascular | 18 |
| Neurological and mental health | 7 |
| Musculoskeletal | 6 |
| Immune system | 3 |
| Oncology | 3 |
| Reproductive and sexual health | 3 |
| Dermatology | 2 |
| Antimicrobial and infectious disease | 1 |
Registered clinical trials
12 of 16 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 22 · Active, not recruiting: 9 · Recruiting: 2 · Available (expanded access): 1
Phase not applicable: 1 · Phase 1: 15 · Phase 2: 4 · Phase 3: 14
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access
PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses
- Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · June 29, 2026 · Meta-analysis · cited 0 times
PMID 42371360 · DOI 10.1007/s40292-026-00812-6 · Reviews and meta-analyses
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Cardiology in review · February 19, 2026 · Meta-analysis · cited 1 times
PMID 41711462 · DOI 10.1097/crd.0000000000001209 · Reviews and meta-analyses
- Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Endocrinology, diabetes & metabolism · September 1, 2025 · Meta-analysis · cited 31 times · open access
PMID 40988099 · DOI 10.1002/edm2.70113 · Reviews and meta-analyses
- Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
The Journal of clinical endocrinology and metabolism · September 1, 2025 · Meta-analysis · cited 45 times
PMID 40489581 · DOI 10.1210/clinem/dgaf336 · Reviews and meta-analyses
- Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Journal of diabetes · April 1, 2025 · Meta-analysis · cited 28 times · open access
PMID 40207414 · DOI 10.1111/1753-0407.70082 · Reviews and meta-analyses
- Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
Diabetes technology & therapeutics · February 6, 2025 · Meta-analysis · cited 10 times
PMID 39911047 · DOI 10.1089/dia.2024.0533 · Reviews and meta-analyses
- Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.
Obesity pillars · January 30, 2025 · Meta-analysis · cited 32 times · open access
PMID 39980735 · DOI 10.1016/j.obpill.2025.100162 · Reviews and meta-analyses
- Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
Expert review of clinical pharmacology · January 16, 2025 · Meta-analysis · cited 9 times
PMID 39817343 · DOI 10.1080/17512433.2025.2450254 · Reviews and meta-analyses
- Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
American journal of therapeutics · July 1, 2024 · Meta-analysis · cited 4 times
PMID 38976545 · DOI 10.1097/mjt.0000000000001743 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England journal of medicine · June 26, 2023 · Randomized controlled trial · cited 1,155 times
PMID 37366315 · DOI 10.1056/nejmoa2301972 · Human clinical research
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet (London, England) · June 26, 2023 · Randomized controlled trial · cited 419 times
PMID 37385280 · DOI 10.1016/s0140-6736(23)01053-x · Human clinical research
- What is the pipeline for future medications for obesity?
International journal of obesity (2005) · February 1, 2024 · Review · cited 331 times · open access
PMID 38302593 · DOI 10.1038/s41366-024-01473-y · Reviews and meta-analyses
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Cell metabolism · August 18, 2022 · Animal study · cited 312 times · open access
PMID 35985340 · DOI 10.1016/j.cmet.2022.07.013 · Animal studies
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nature medicine · June 10, 2024 · Randomized controlled trial · cited 307 times · open access
PMID 38858523 · DOI 10.1038/s41591-024-03018-2 · Human clinical research
Latest publications
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.
The New England journal of medicine · October 21, 2026 · Randomized controlled trial · cited 0 times
PMID 42904878 · DOI 10.1056/nejmoa2611477 · Human clinical research
- Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile.
Journal of molecular histology · October 15, 2026 · Animal study · cited 0 times · open access
PMID 42878930 · DOI 10.1007/s10735-026-11013-9 · Animal studies
- GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
Acta diabetologica · October 14, 2026 · Review · cited 0 times · open access
PMID 42873315 · DOI 10.1007/s00592-026-02812-3 · Reviews and meta-analyses
- From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.
Frontiers in pharmacology · October 13, 2026 · Review · cited 0 times · open access
PMID 42947668 · DOI 10.3389/fphar.2026.1784959 · Reviews and meta-analyses
- Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.
Pharmaceutics · October 9, 2026 · Review · cited 0 times · open access
PMID 42942810 · DOI 10.3390/pharmaceutics18101277 · Reviews and meta-analyses
- Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
JAMA · October 9, 2026 · Editorial, letter or other · cited 0 times
PMID 42853576 · DOI 10.1001/jama.2026.20514 · Commentary and other
- Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.
BMJ case reports · October 7, 2026 · Case report · cited 0 times · open access
PMID 42843917 · DOI 10.1136/bcr-2026-276106 · Human clinical research
- Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
BMJ (Clinical research ed.) · October 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42823062 · DOI 10.1136/bmj-2026-101016 · Commentary and other
- Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide.
JAMA network open · October 1, 2026 · Not yet classified · cited 0 times · open access
PMID 42873503 · DOI 10.1001/jamanetworkopen.2026.38929 · Not yet classified
- Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Lancet (London, England) · October 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42849462 · DOI 10.1016/s0140-6736(26)01987-2 · Commentary and other
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: LY3437943; Retarutide; Retatrutide
((TITLE_ABS:"LY3437943" OR CHEM:"LY3437943" OR TITLE_ABS:"LY 3437943" OR CHEM:"LY 3437943") OR (TITLE_ABS:"Retarutide" OR CHEM:"Retarutide") OR (TITLE_ABS:"Retatrutide" OR CHEM:"Retatrutide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Retatrutide research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/retatrutide